Literature DB >> 6187015

Artificial Salmonella vaccines.

S B Svenson, A A Lindberg.   

Abstract

Mesh:

Substances:

Year:  1983        PMID: 6187015     DOI: 10.1159/000407424

Source DB:  PubMed          Journal:  Prog Allergy        ISSN: 0079-6034


× No keyword cloud information.
  6 in total

1.  Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.

Authors:  L C Paoletti; D L Kasper; F Michon; J DiFabio; H J Jennings; T D Tosteson; M R Wessels
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

2.  Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.

Authors:  Francis Michon; Catherine Uitz; Arun Sarkar; Anello J D'Ambra; Maryline Laude-Sharp; Samuel Moore; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2006-08

3.  Salmonella typhi O:9,12 polysaccharide-protein conjugates: characterization and immunoreactivity with pooled and individual normal human sera, sera from patients with paratyphoid A and B and typhoid fever, and animal sera.

Authors:  L Aron; J Di Fabio; F C Cabello
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

4.  Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

Authors:  J A Roberts; M B Kaack; G Baskin; S B Svenson
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

5.  Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

Authors:  A F Verheul; A A Versteeg; M J De Reuver; M Jansze; H Snippe
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

6.  Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide.

Authors:  J W Zigterman; J E van Dam; H Snippe; F T Rotteveel; M Jansze; J M Willers; J P Kamerling; J F Vliegenthart
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.